RESUMEN
Climate change is occurring rapidly, and this crisis should now be recognized as a "global emergency". It is one of the major global health threats brought about by global warming, resulting from human activity due in large part to increasing levels of greenhouse gases. The ongoing climate crisis poses significant risks to women, pregnant mothers, unborn fetuses and offspring, who were exposed in-utero to climate stressors, especially those in marginalized communities where effects are magnified. A focus on education, research, and advocacy in responding to changing health consequences and global awareness are key to educating our professional healthcare providers, patients, the lay public, key personnel in the government and other leaders, and by making the changes necessary to address this crisis. Building on the pillars that FIGO has identified (advocacy, research interpretation, capacity building, and education), and following the footsteps of the FIGO Committee on "Climate Change and Toxic Environmental Exposures", the baby steps yet focussed efforts taken by AOFOG through its recently formed "Climate Change & Pollution Working Group" will be highlighted in this review article. After all, investing in the health of women is investing in the health of current and future generations, and we, as healthcare providers along with health professional organizations should be in the forefront of environmental health advocacy to save the present generation and future generations through engagement as public opinion leaders.
RESUMEN
The Sustainable Development Goals were finalized in September 2015 by following and expanding Millennium Development Goals with newer targets under the principle of 'leaving no one behind'. One of the 17 goals is devoted to health (Goal number 3). Understanding the health care utilization behavior is essential to attain the health goal by providing adequate and quality health services. The study seeks to understand the health care utilization behavior and its determinants in Malda district, India. For this study, the primary data are collected through a household survey with a pre-designed schedule. For that, for a comparative discussion, Englishbazar and Chanchal- II blocks have been chosen by purposive sampling considering the best and worst health conditions, respectively. The sample size was 100 families for each block. Analytical methods like chi-square, correlation, and regression analysis are used for the study. The four categories of treatment patterns that have been recognized in the study area; are self-treatment, government institution, qualified doctors and private institution, and the presence of quack doctors. People's education and income were the confounding factors of such treatment patterns. Many of the respondents are getting treatment from quack doctors or rely on self-treatment based on their very little knowledge of medicine, resulting from a lack of awareness among local communities. It may be concluded that besides socio-economic factors, the availability of insufficient health care facilities influences the health care utilization behavior in the study area.
RESUMEN
BACKGROUND: Initial introduction of HPV vaccination from 2006 to 2008 was largely confined to high-income countries (HIC), such as Australia, the United States, and Europe, where cervical cancer incidence is lowest. Much of the post-introduction literature has come from HICs, with a focus on coverage levels achieved, provider acceptability and early impact of vaccination on disease endpoints. However, there are a few literature evaluating the mechanics of delivery, feasibility of the health system and acceptability from low and middle income countries (LMICs). The primary objective was to evaluate the feasibility, acceptability and safety of two dose HPV vaccination in adolescent girls between 9-14 years. METHODS: After an orientation camp followed by filling up of prevaccine questionnaires by parents on HPV related diseases and its vaccines and informed consent, girls between9-14years were vaccinated. They were asked to report any side effects in the next 24 hours after each dose. Parents were contacted on Day 7 and Day 30 to enquire about any side effects . Total 3 visits were required i.e two for the vaccination and one visit at 7th month post completion of second dose. To estimate the acceptability, successful completion of two doses by at least 80% of the girls were measured. For measurement of acceptability, either of the parents were recalled along with their daughter at 7th month and were asked to fill up a pre-set questionnaire. RESULTS: After institutional ethical clearance, 555 girls were recruited in the study from rural parts of West Bengal, India between July, 2017 to November, 2017. Out of which, 544 girls (98%) received their 2nd dose between January, 2018 and May, 2018 without any serious adverse effects. No serious adverse effect was reported on follow up till December, 2019. CONCLUSION: The introduction of HPV vaccination is feasible in large scale and the vaccine is well accepted and safe.
.
Asunto(s)
Programas de Inmunización , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/uso terapéutico , Aceptación de la Atención de Salud , Neoplasias del Cuello Uterino/prevención & control , Adolescente , Niño , Atención a la Salud , Países en Desarrollo , Estudios de Factibilidad , Femenino , Humanos , IndiaRESUMEN
Human papillomavirus (HPV) vaccination offers an excellent prospect for the primary prevention of cervical cancer. The bivalent and quadrivalent vaccines are both available in India. The nonavalent vaccine is licensed but not yet available. However, there still remain controversies regarding the vaccination of older women, immunocompromised females and other special groups. To provide recommendations for HPV vaccination in India. The Federation of Obstetric and Gynecological Societies of India (FOGSI) convened an expert group on cervical cancer prevention to formulate good clinical practice recommendations (GCPR) with respect to vaccine efficacy and safety, target groups, optimal timing and dosing schedules. HPV vaccines are licensed for females aged 9-45 years in India and have been seen to be safe and effective. FOGSI recommends HPV vaccination of all girls <15 years of age as the best target group, in whom two-doses at an interval of 6 months, extendable to 18 months, are recommended. Three-doses are recommended in girls >15 years of age, immunocompromised persons and sexual assault survivors. Older women and women with abnormal screening results may be vaccinated with an understanding that vaccination does not protect against already acquired infections and screening has to continue. Single-dose vaccination results are promising. Increased awareness is required to reduce vaccine hesitancy. HPV vaccination should be the priority to achieve the elimination of cervical cancer. The introduction of affordable HPV vaccines and reduced dose schedules will improve coverage.